EXCLUSIVE: Actinium Pharmaceuticals, Inc. Chairman & CEO, Sandesh Seth To Appear On Benzinga’s Live TV At 11:05 a.m. ET
Click To Tune In Here... https://www.youtube.com/watch?v=nzT2jAbCzeI
Why Sonnet BioTherapeutics Shares Surged Over 66%; Here Are 63 Biggest Movers From Yesterday
Gainers
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) climbed 66.4% to close at $1.93 on Monday after the company announced an agreement with Janssen for the evaluation of three Sonnet product candidates.
B. Riley Securities Maintains Buy on Actinium Pharmaceuticals, Raises Price Target to $18
B. Riley Securities analyst Yuan Zhi maintains Actinium Pharmaceuticals (AMEX:ATNM) with a Buy and raises the price target from $16 to $18.
HC Wainwright & Co. Maintains Buy on Actinium Pharmaceuticals, Raises Price Target to $53
HC Wainwright & Co. analyst Joseph Pantginis maintains Actinium Pharmaceuticals (AMEX:ATNM) with a Buy and raises the price target from $45 to $53.
With Upcoming Pivotal Data, Analyst Sees 145% Upside In Actinium
Cantor Fitzgerald initiated coverage on Actinium Pharmaceuticals Inc (NYSE:ATNM) with an Overweight rating and a price target of $20, almost an upside…
B. Riley Securities Initiates Coverage On Actinium Pharmaceuticals with Buy Rating, Announces Price Target of $16
B. Riley Securities analyst Yuan Zhi initiates coverage on Actinium Pharmaceuticals (AMEX:ATNM) with a Buy rating and announces Price Target of $16.
Actinium Pharmaceuticals Granted U.S. Patent #11,364,235 Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5393&f=G&l=50&d=PTXT&p=108&S1=20220621&OS=20220621&RS=20220621
Benzinga’s Daily Brief On Trending Tickers For April 12, 2022: Veru, Kohl’s Corporation, BioCardia, And More
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the